05 sep: Lønstigninger er urealistiske
08 sep: Boligfesten er slut
07-09-2006 11:15:00

STRATEC raises sales and earnings forecast for 2008 to 2010

Birkenfeld, September 7, 2006

STRATEC Biomedical Systems AG today published an ad-hoc announcement

(statutory company announcement) with its sales and earnings forecast

for the 2006 and 2007 financial years. Pursuant to this announcement,

the company assumes that it will be possible to increase its sales

for 2006 to between Euro 65 million and Euro 68 million (sales

corridor) and for 2007 to between Euro 75 million and Euro 78 million

(sales corridor) and to increase its earnings before tax (EBT) to

between Euro 10.5 million and Euro 11 million in 2006 (earnings

corridor) and to between Euro 14 million and Euro 15 million in 2007

(earnings corridor).

In view of the considerable increase in the basis for the 2007

financial year, based on its current planning the company expects to

achieve an annual average growth rate (CAGR) of more than 11% in the

case of sales and of more than 16% for earnings before tax (EBT) from

2008 up to and including 2010.

As a result of the basis effect (higher basis in 2007) and the

shifting of the period under consideration by one year from 2008 the

average annual growth rate (CAGR) for our key sales and earnings

figures is lower in percentage terms, yet higher in absolute terms,

in the long-term forecast (for 2008 to 2010) than in the forecast

published in December 2005 (for 2007 to 2009). Assuming that the

targets stated in our long-term forecast are met, the average annual

growth rate (CAGR) reported by the STRATEC Group for the financial

years from 2000 to 2010 would amount to more than 25% in the case of

sales and to more than 34% in the case of earnings before tax (EBT).

The forecast for 2008 to 2010 takes only limited account of the

conclusion of outstanding new development and supply agreements for

new analyzer system families with existing and new customers.

The new budget figures are considerably higher than the internal

budget targets most recently forecast in December 2005. These

forecast that the sales for the 2006 financial year would increase to

Euro 55 million to Euro 59 million (sales corridor) and that earnings

before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million

(earnings corridor). An average annual growth rate (CAGR) of more

than 15% in the case of sales and of more than 22% for earnings

before tax (EBT) was forecast for the subsequent 2007 to 2009

financial years.

The annual average growth (CAGR) reported for the financial years

from 2000 up to and including 2005 amounted to more than 32% in terms

of sales and to more than 40% in the case of earnings before tax

(EBT).

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 maj
PNDORA
  Jeg har flere gange analyseret Pandora, senest den 20 april og inden da efter årsregnskabet i febr..
115
22 maj
 
Hej IceT : Det er kloge ord, du kommer med her. Jeg trak mig tilbage, da jeg var 53 år. Min arbejdsp..
32
20 maj
PNDORA
LCB84 Earnings yield er jo den omvendte P/E, og dermed det direkte afkast du får af den pris aktien ..
31
23 maj
 
For nogle af mine kunder, laver jeg en kvartals-analyse over, hvordan de Nordiske selskabers indtjen..
25
20 maj
PNDORA
investor1 Her er lidt indspark til din vurdering. Pandora tjener aktuelt 53 kr. pr. aktie om året. J..
21
19 maj
BAVA
tak til Kranen og andre, for at smide lidt guld ud i form af info.   Men guldet kom først her:   htt..
20
19 maj
BAVA
Slap dog af bamse. 1.000 i 2017 er et temmelig vildt gæt. Og det er vel at mærke et gæt, du giver jo..
15
24 maj
PNDORA
Nej for det er Breaking news.
12
23 maj
 
Man korser sig når man ser hvad nogle mennesker kan finde på og skrive, blot fordi de kan gøre det a..
12
23 maj
 
Hold øje med at politikere og andre nu som sædvanligt vil mane os til "at stå sammen" og "ikke lade ..
12

Dong-topchef om salg af oliedivision: Den samlede pris er rigtig fin

24-05-2017 16:33:25
Flere iagttagere har kaldt salgsprisen for Dongs olie- og gasforretning lav, men hos energiselskabet selv mener man, at prisen er rigtig god, når man ser på det samlede regnestykke.Sådan lyder det fra Dongs administrerende direktør, Henrik Poulsen, efter at selskabet onsdag har gjort klar til et salg til den britiske kemikoncern Ineos.- Vi har fået en rigtig fin pris for forretningen. Vi har fået ..

Nordex-Acciona/dir: Har rigtig godt momentum i USA

24-05-2017 12:06:06
Den tyske vindmølleproducent Nordex, der for nylig overtog Acciona Windpower, har USA som et af nøglemarkederne, hvor selskabet venter at kunne fortsætte væksten fra et travlt 2017.- Vi har et rigtigt godt momentum i markedet, og i år kommer vil til at installere tæt ved 800 megawatt i USA siger Thomas Donoghue, som er salgschef for Nordex-Acciona på det nordamerikanske marked, til Ritzau Finans p..

Aktier/åbning: Salg af oliebiks sender Dong op i lyserødt marked

24-05-2017 09:07:05
Lige da alt så ud til at være ganske fredeligt før åbningen af det danske aktiemarked onsdag før den lange weekend, strøg Dong i fokus med nyheden om, at olie- og gasforretningen bliver solgt til kemivirksomheden Ineos.Dong satte forretningsdelen til salg i efteråret, og Dong har selv flere gange sagt, at et frasalg var ventet i løbet af 2017. Prisen kan løbe op i 8,7 mia. kr. og ændrer ikke ved 2..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. maj 2017 00:05:36
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB1 - 2017-05-26 00:05:36 - 2017-05-26 00:05:36 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x